

Original Research Article

Prevalence of High-risk HPV infection in women presenting with chronic leucorrhoea at Kenyatta National Hospital, Nairobi City County, Kenya

ABSTRACT

Background: Chronic leucorrhoea is the most common symptom caused by infections of the vagina itself or infections/inflammation of the cervix. These inflammations are mostly associated with *Candida* spp, the parasite *Trichomonas vaginalis* infection, and the Human papillomavirus. Oncogenic HPV sub-types 16, 18, 31, 33 and 45 have been greatly associated and contributed to nearly 70% of all cervical cancers. HPV infections may clear within a period of up to 2 years. However, for every 1 million women infected with the virus, approximately 10% (100,000) will develop cervical dysplasia.

Objective: This study aimed to investigate the prevalence of HPV infection in women presenting with chronic leucorrhoea at Kenyatta National Hospital, Nairobi City County in the Gynecology and Obstetrics department.

Study design: The study adopted a prospective cross-sectional design.

Place and Duration of Study: Department of Gynecology and Obstetrics Kenyatta National Hospital between October to December 2023.

Methodology: The study included 107 women presenting with chronic leucorrhoea aged 18 years and above who were purposely sampled and screened for high-risk HPV genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68 and 73 using real-time PCR.

Results: Among the 107 women included in this study, 38 of them (35.5%) tested positive for high-risk HPV strain whereas 69 (64.5%) tested negative. The highest positives were observed in HPV 16 (42.1%), then other hrHPV (36.8%), and finally HPV 18 at 21.0%. Out of all the risk factors analyzed none was found to have a statistically significant association with HPV infection.

Conclusion: The prevalence of high-risk HPV infection in women presenting with chronic leucorrhoea was 35.5% in this study with genotype 16 being the most prevalent. Of all the risk factors analyzed, none had a statistically significant association with high-risk HPV infection.

Keywords: Leucorrhoea, dysplasia, colposcopy, hysterectomy

1. INTRODUCTION

According to estimates from the World Health Organization, around 530,000 women globally receive a cervical cancer diagnosis each year, with 275,000 of them losing their lives to the illness. It is well known that cervical cancer ranks third among cancers that affect women worldwide, with about 70% of cases occurring in underdeveloped nations. Current estimates in Kenya indicate that every year 5236 women are diagnosed with cervical cancer and 3211 die from the disease [1].

It has been established that certain human papillomavirus (HPV) genotypes are the cause of cervical cancer. Geographically limited heterogeneity exists among the many kinds of HPV, and the relationship between HPV and cervical cancer is a worldwide reality [2].

The primary cause of cervical cancer is HPV infection of the cervix, and nearly all cases of invasive cervical cancer will have high-risk HPV DNA detected in them thanks to modern testing methods. Ineffective cell-mediated immunity is one of the main factors contributing to the development and progression of cervical neoplasia in women who are frequently infected [3].

More than 40 HPV genotypes have been found in anogenital mucosa samples, and they are sexually transmitted. The high-risk (HR) group of HPV genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 is associated with an increased risk of cervical cancer [4].

The main stages of cervical oncogenesis are invasion, viral persistence, clonal development of the persistently infected epithelium to cervical pre-cancer, and infection of the metaplastic epithelium of the cervical transformation zone with high-risk HPV infection [5].

One of the leading causes of illness and death in sub-Saharan Africa is HPV-associated cervical cancer. In most countries, the high incidence rate of cervical cancer has been linked to a lack of effective efforts and long-term programs and services for prevention. In Eastern Africa, the prevalence of cervical HPV infection is estimated to be 35.8% among women at any given time, and HPV 16 or 18 is linked to 76.5% of invasive cervical cancer cases. Furthermore, the fact that just 0.6% of Kenyan women between the ages of 18 and 69 are checked every three years—that is, 1.6% of urban women and 0.4% of rural women—indicates that screening procedures are inadequate and that overall coverage is extremely low [6].

Significant information was generated by this investigation, including pertinent data on the prevalence of HR HPV infection.

2. MATERIAL AND METHODS

Study Design

This was a prospective cross-sectional study where 107 women presenting with chronic leucorrhoea at Kenyatta National Hospital gynecology and obstetrics department were purposely sampled and screened for high-risk HPV genotypes using real-time PCR between October to December 2023. The current study included women who were at least 18 years of age and had given consent to participate. Demographic data was collected by administering a questionnaire among the study participants. Women who were on their periods, who had undergone a hysterectomy, or refused to give consent were excluded from the study.

2.1 Obtaining cervical samples

Before the collection of cervical samples participants were thoroughly counseled and instructed on all procedures to be carried out so that they could give informed consent. A single-use, sterile speculum of appropriate size was lubricated using plain tap water and gently introduced into the vagina. To visualize the cervix, the speculum was manipulated so that it expounded and opened the vaginal canal. Scrapping of the endocervix and ectocervix was done using a cytobrush by rotating it thrice. The brush was then vigorously stirred in a

cartridge containing HPV fixative then capped, labeled, and sent to the molecular laboratory for analysis

2.1.1 Processing of samples for HPV DNA Detection

High-risk HPV DNA detection was done using real-time PCR. The detection protocol was based on the commercial Kit V31-100/F FRT. All the reagents were prepared following the manufacturer's instructions on the assay day. Extraction of DNA material and amplification was done as per the standard operating procedures and results interpretation was done.

2.1.1.1 Data Analysis

The HPV DNA results were first recorded in an Excel spreadsheet and then imported into a software program (IBM SPSS Inc. application software version 21.0.1.2010) for analysis of the dependent and independent variables. Summarized results were tabulated to display proportions and P values. A Chi-square test was performed to establish if there was a significant association between high-risk HPV infection and the demographic factors considered in this study. A P value of less than 0.05 was considered statistically significant at a confidence interval of 95%.

UNDER PEER REVIEW

3. RESULTS

In this study, a total of 107 women were enrolled. Their ages ranged from 24 – 57 years. Out of the 107 women enrolled, 38 (35.5%) tested positive for high-risk HPV infection while 69 (64.5%) tested negative (figure 1). Out of the 38 women who tested positive for high-risk HPV infection, 16 (42.1%) tested positive for genotype 16, 14 (36.8%) were positive for other hrHPV genotypes and 8 (21.1%) tested positive for genotype 18.(Figure 2).

Of all the risk factors analyzed, none was found to have any statistically significant association with high-risk HPV infection. Table 1 shows a cross-tabulation of Age of Participants against high-risk HPV infection. The highest prevalence of HPV infection was noted in the age bracket of 30-34 years (44.7%). The brackets of 50-54 years and 55-60 years each recorded the lowest each recording only 1 woman (2.6%). However, there was no statistically significant association between the age of the participants and high-risk HPV infection ($p = .619$) {Table 1}.

Out of the 107 women recruited, 92 (86.0%) had no history of drug abuse whereas 15 (14.0%) had a run-in with a substance in the past. The majority of the women reported to have only one sexual partner (96.3%). Most of the participants (66) reported to have engaged in their first intercourse at the age of 18 years (Table 2)

Among the 107 women recruited, 47 (43.9%) were married, 42 (39.3%) were single, 13 (12.1%) were widowed and 5 women (4.7%) were divorced. There was no statistically significant association between the marital status of the participants and high-risk HPV infection ($p=.112$). On assessing the level of education, the majority of the participants (47) had attained secondary education level (43.3%) while only 26 had gone up to college level (24.3%). Under the type of contraceptive use, the most preferred method for family planning was condoms with 38 women (35.5%) while pills were the most unpopular with only 3 women (2.4%) {Table 3}.

Table1: Comparison of age versus high-risk HPV infection

Age (Years)	Final HPV Result			P-value
	Total	Negative	Positive	
18-23	0 (0.0%)	0 (0.0%)	0 (0.0%)	.619
24-29	2 (1.9%)	2 (2.89%)	0 (0.0%)	
30-34	42 (39.3%)	25 (36.23%)	17 (44.73%)	
35-39	22 (20.6%)	16 (23.18%)	6 (15.78%)	
40-44	20 (18.7%)	11 (15.94%)	9 (23.68%)	
45-49	17 (15.9%)	13 (18.84%)	4 (10.52%)	
50-54	2 (1.9%)	1 (1.44%)	1 (2.63%)	
55-59	2 (1.9%)	1 (1.44%)	1 (2.63%)	
Total Number	107(100%)	69 (100%)	38 (100%)	

Table 2. History of Substance Abuse, number of sexual partners, age at first intercourse versus high-risk HPV infection

History of substance abuse	Final HPV result			P-value
	Total	Negative	Positive	
NO	92 (86.0%)	61 (88.4%)	31 (81.57%)	.330
YES	15 (14.0%)	8 (11.59%)	7 (18.42%)	
Total number	107(100.0%)	69 (100%)	38 (100%)	

Number of sexual partners				
One	103 (96.3%)	66 (95.6%)	37 (97.36%)	.654
More than one	4 (3.7%)	3 (4.34%)	1 (2.63%)	
Total number	107 (100.0%)	69 (100%)	38 (100%)	
Age at first intercourse				
16	2 (1.9%)	1 (1.44%)	1 (2.63%)	.202
17	7 (6.5%)	5 (7.24%)	2 (5.26%)	
18	66 (61.7%)	44 (63.76%)	22 (57.89%)	
19	19 (17.8%)	9 (13.04%)	10 (26.31%)	
20	12 (11.2%)	9 (13.04%)	3 (7.89%)	
21	1 (0.9%)	1 (1.44%)	0 (0.0%)	
Total number	107 (100%)	69 (100%)	38 (100%)	

Table 3. Comparison of Marital status, Level of Education, Choice of Family Planning versus high-risk HPV infection

Marital status	HPV result			P-value
	Total	Negative	Positive	
Single	42 (39.3%)	26 (37.68%)	16 (42.1%)	.112
Married	47 (43.9%)	29 (42.02%)	18 (47.36%)	
Divorced	5 (4.7%)	2 (2.89%)	3 (7.89%)	
Widowed	13 (12.1%)	12 (17.39%)	1 (2.63%)	
Total number	107(100%)	69 (100%)	38 (100%)	
Education				.202
Primary	34 (31.8%)	25 (36.23%)	9 (23.68%)	
Secondary	47 (43.9%)	26 (37.68%)	21 (55.26%)	
College	26 (24.3%)	18 (26.08%)	8 (21.05%)	
Total number	107 (100%)	69 (100%)	38 (100%)	
Family planning method				.675
None	22 (20.6%)	14 (20.28%)	8 (21.05%)	
Pills	3 (2.8%)	3 (4.34%)	0 (0%)	
Implant	20 (18.7%)	11 (15.94%)	9 (23.68%)	
Condom	38 (35.5%)	26 (37.68%)	12 (31.57%)	
Injection	14 (13.1%)	8 (11.59%)	6 (15.78%)	
IUD	10 (9.3%)	7 (10.14%)	3 (7.89%)	
Total number	107 (100%)	69 (100%)	38 (100%)	




Fig 1. Prevalence of high-risk HPV




Fig 2. Frequency of HPV 16, HPV 18, and other hrHPV

DISCUSSION

The proportion of tested women who were found to be positive for the papillomavirus was 35.5%. Genotype 16 was found to be the most prevalent (42.10%) followed by other hrHPV (36.8%) and lastly HPV 18 (21.05%). Out of these factors, none were found to have a significant statistical association with acquiring the HPV infection. This prevalence was closer to the prevalence of a study done by Vinodhini *et al.*, whose prevalence was 32.1%. Their study also found HPV 16 to be most prevalent in their analysis at 9.5% (7). Ziziphoet *al.*, a study carried out in South Africa also got a prevalence of 35.0% with HPV 16 being the most at 11.6%. Denny *et al.* study also found HPV 16 to be the most prevalent at 51.2% (9). However, studies by Okoye *et al.*, showed that HPV 53 and HPV 31 were the most prevalent at 7.3% and 5.3% respectively (10). A study by Meulenet *al.*, in Tanzania found that HPV 18 was more prevalent at 17.5% (12). Taku *et al.*, study also showed the highest prevalence to be of HPV 35 (23.9%) (11).

Watson-Jones *et al.*, study showed that age had a significant association with contracting HPV (15). This concurred with Sangwa-Lugoma *et al.*, a study that said the younger generation was more at risk than older women (16). However, Sinayobye *et al.* showed a negative association between old age and acquiring HPV infection (14). However, Ermel *et al.*, and Kuguyo *et al.*, found that age had no statistically significant association with acquiring HPV infection in the tested women (18) (23).

Osazuwa-Peters *et al.* study also concluded that there was no significant statistical association between drinking alcohol or smoking and HPV infection (22). Sangwa-Lugoma *et al.*, the study showed that smoking or chewing tobacco had a significant association with getting HPV infection (16). Mbulawa *et al.* and Swai *et al.* also concurred with this by stating that binge drinking alcohol increased the risk of getting infected by HPV (8) (21).

A study in Rwanda by Sinayobye *et al.* also showed no significant statistical association between the number of lifetime sexual partners and HPV infection (14). Watson-Jones *et al.*, study also showed that there was no significant statistical association between several lifetime sexual partners (15). Taku *et al.*, study showed that >3 lifetime sexual partners increased the odds of getting HPV infection (11). Vinodhini *et al.* concurred that increased sexual partners also increased the risk of getting HPV infection (7).

Mchomee *et al.*, study showed that women who were at an early age at first intercourse were at risk of getting HPV infection (17). This agreed with a similar study done by Kirui *et al.*, which also concluded that early sexual debut increased the risk of getting HPV (20).

Houlihan *et al.*, study concluded that there is no association between early sexual intercourse

and acquiring HPV infection (24). Nang *et al.* said that women who attained secondary education had a reduced risk of contracting HPV infection compared to those with no form of education (25). Manga *et al.*, also proved that level of education was significantly associated with HPV infection (27). Ali *et al.* study showed that level of education had no statistical significance. They also showed that occupation had a positive association with acquiring HPV infection (26).

Vinodhini *et al.* study stated that the use of contraceptives contributed to an increased risk of acquiring HPV infection (7). Molano *et al.* showed that using oral contraceptives and IUDs increased the risk of acquiring HPV significantly (21). Sangwa-Lugoma *et al.*, study showed that divorced women had the highest frequency of HPV positive results (16).

4. CONCLUSION

The prevalence of High-risk HPV infection in women presenting with chronic leucorrhoea was 35.5% in this study with genotype 16 being the most prevalent. None of the risk factors analyzed had a statistically significant association with high-risk HPV infection.

CONSENT

The authors affirmed that all participants were briefed concisely and clearly on all procedures about to be carried out on them after both verbal and written consent were obtained from them.

ETHICAL APPROVAL

The authors also affirmed that the study protocols had been gone through and cleared by the Kenyatta National Hospital Ethical Review Committee (P293/03/2023).

REFERENCES

1. Zhang S, Xu H, Zhang L, Qiao Y. Cervical cancer: Epidemiology, risk factors and screening. *Chinese Journal of Cancer Research*. 2020 Dec 12;32(6):720.
2. Yadav K, Cree I, Field A, Vielh P, Mehrotra R. Importance of cytopathologic diagnosis in early cancer diagnosis in resource-constrained countries. *JCO Global Oncology*. 2022 Feb;8: e2100337.
3. Rashid S, Labani S, Das BC. Knowledge, awareness and attitude on HPV, HPV vaccine and cervical cancer among the college students in India. *PLoS one*. 2016 Nov 18;11(11): e0166713.
4. Franco EL, Schlecht NF, Saslow D. The epidemiology of cervical cancer. *The Cancer Journal*. 2003 Sep 1;9(5):348-59.
5. Orang'o EO, Were E, Rode O, Muthoka K, Byczkowski M, Sartor H, Vanden Broeck D, Schmidt D, Reuschenbach M, von Knebel Doeberitz M, Bussmann H. Novel concepts in cervical cancer screening: a comparison of VIA, HPV DNA test and p16 INK4a/Ki-67 dual stain cytology in Western Kenya. *Infectious Agents and Cancer*. 2020 Dec; 15:1-.
6. Bruni LB, Barrionuevo-Rosas L, Albero G, Serrano B, Mena M, Gómez D, Muñoz J, Bosch FX, De Sanjosé S. Human papillomavirus and related diseases report. *ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre)*. 2019 Jun;307-.
7. Vinodhini K, Shanmughapriya S, Das BC, Natarajaseenivasan K. Prevalence and risk factors of HPV infection among women from various provinces of the world. *Archives of gynecology and obstetrics*. 2012 Mar; 285:771-7.

8. Mbulawa ZZ, Van Schalkwyk C, Hu NC, Meiring TL, Barnabas S, Dabee S, Jaspan H, Kriek JM, Jaumdally SZ, Muller E, Bekker LG. High human papillomavirus (HPV) prevalence in South African adolescents and young women encourages expanded HPV vaccination campaigns. *PloS one*. 2018 Jan 2;13(1): e0190166.
9. Denny L, Adewole I, Anorlu R, Dreyer G, Moodley M, Smith T, Snyman L, Wiredu E, Molijn A, Quint W, Ramakrishnan G. Human papillomavirus prevalence and type distribution in invasive cervical cancer in sub-Saharan Africa. *International journal of cancer*. 2014 Mar 15;134(6):1389-98.
10. Okoye JO, Ofodile CA, Adeleke OK, Obioma O. Prevalence of high-risk HPV genotypes in sub-Saharan Africa according to HIV status: a 20-year systematic review. *Epidemiology and Health*. 2021;43.
- 11.. Taku O, Businge CB, Mdaka ML, Phohlo K, Basera W, Garcia-Jardon M, Meiring TL, Gyllensten U, Williamson AL, Mbulawa ZZ. Human papillomavirus prevalence and risk factors among HIV-negative and HIV-positive women residing in rural Eastern Cape, South Africa. *International Journal of Infectious Diseases*. 2020 Jun 1; 95:176-82.
12. Meulen JT, Eberhardt HC, Luande J, Mgaya HN, Chang-Claude J, Mtiro H, Mhina M, Kashajja P, Ockert S, Yu X, Meinhardt G. Human papillomavirus (HPV) infection, HIV infection and cervical cancer in Tanzania, east Africa. *International Journal of Cancer*. 1992 Jun 19;51(4):515-21.
13. Taku O, Businge CB, Mdaka ML, Phohlo K, Basera W, Garcia-Jardon M, Meiring TL, Gyllensten U, Williamson AL, Mbulawa ZZ. Human papillomavirus prevalence and risk factors among HIV-negative and HIV-positive women residing in rural Eastern Cape, South Africa. *International Journal of Infectious Diseases*. 2020 Jun 1; 95:176-82.
14. Sinayobye JD, Sklar M, Hoover DR, Shi Q, Dusingize JC, Cohen M, Mutimura E, Asiimwe-Kateera B, Castle PE, Strickler H, Anastos K. Prevalence and risk factors for High-Risk Human Papillomavirus (hrHPV) infection among HIV-infected and Uninfected Rwandan women: implications for hrHPV-based screening in Rwanda. *Infectious agents and cancer*. 2014 Dec; 9:1-1.
15. Watson-Jones D, Baisley K, Brown J, Kavishe B, Andreassen A, Changalucha J, Mayaud P, Kapiga S, Gumodoka B, Hayes RJ, de Sanjosé S. High prevalence and incidence of human papillomavirus in a cohort of healthy young African female subjects. *Sexually transmitted infections*. 2013 Aug 1;89(5):358-65.
16. Sangwa-Lugoma G, Ramanakumar AV, Mahmud S, Liaras J, Kayembe PK, Tozin RR, Lorincz A, Franco EL. Prevalence and determinants of high-risk human papillomavirus infection in women from a sub-Saharan African community. *Sexually transmitted diseases*. 2011 Apr 1:308-15.
17. Mchome BL, Kjaer SK, Manongi R, Swai P, Waldstroem M, Iftner T, Wu C, Mwaiselage J, Rasch V. HPV types, cervical high-grade lesions and risk factors for oncogenic human papillomavirus infection among 3416 Tanzanian women. *Sexually Transmitted Infections*. 2021 Feb 1;97(1):56-62.
18. Ermel A, Tonui P, Titus M, Tong Y, Wong N, Ong'echa J, Muthoka K, Kiptoo S, Moormann A, Hogan J, Mwangi A. A cross-sectional analysis of factors associated with detection of oncogenic human papillomavirus in human immunodeficiency virus-infected and uninfected Kenyan women. *BMC infectious diseases*. 2019 Dec; 19:1-8.
19. Mbulawa ZZ, Somdyala NI, Mabunda SA, Williamson AL. High human papillomavirus prevalence among females attending high school in the Eastern Cape Province of South Africa. *PLoS One*. 2021 Jun 18;16(6): e0253074.
20. Kirui S, Patel K, Orang'o O. Prevalence of high risk HPV in HIV+ and HIV-women with cervical dysplasia at the Moi Teaching and Referral Hospital. *East African Medical Journal*. 2017;94(11):891-900.

21. Swai P, Rasch V, Linde DS, Mchome B, Manongi R, Wu CS, Waldstrom M, Iftner T, Mwaiselage J, Kjaer SK. Persistence and risk factors of high-risk human papillomavirus infection among HIV positive and HIV negative tanzanian women: a cohort study. *Infectious Agents and Cancer*. 2022 Dec;17(1):1-1.
22. Osazuwa-Peters N, Adjei Boakye E, Rohde RL, Ganesh RN, Moiyadi AS, Hussaini AS, Varvares MA. Understanding of risk factors for the human papillomavirus (HPV) infection based on gender and race. *Scientific reports*. 2019 Jan 22;9(1):297.
23. Kuguyo O, Dube Mandishora RS, Thomford NE, Makunike-Mutasa R, Nhachi CF, Matimba A, Dandara C. High-risk HPV genotypes in Zimbabwean women with cervical cancer: Comparative analyses between HIV-negative and HIV-positive women. *PLoS One*. 2021 Sep 28;16(9): e0257324.
24. Houlihan CF, de Sanjosé S, Baisley K, Changanluha J, Ross DA, Kapiga S, Godinez JM, Bozicevic I, Hayes RJ, Watson-Jones D. Prevalence of human papillomavirus in adolescent girls before reported sexual debut. *The Journal of infectious diseases*. 2014 Sep 15;210(6):837-45.
25. Nang DW, Tukirinawe H, Okello M, Tayebwa B, Theophilus P, Sikakulya FK, Fajardo Y, Afodun AM, Kajabwangu R. Prevalence of high-risk human papillomavirus infection and associated factors among women of reproductive age attending a rural teaching hospital in western Uganda. *BMC Women's Health*. 2023 Dec;23(1):1-8.
26. Ali KE, Mohammed IA, Difabachew MN, Demeke DS, Haile T, Ten Hove RJ, Kumssa TH, Woldu ZL, Haile EL, Tullu KD. Burden and genotype distribution of high-risk Human Papillomavirus infection and cervical cytology abnormalities at selected obstetrics and gynecology clinics of Addis Ababa, Ethiopia. *BMC cancer*. 2019 Dec; 19:1-9.
27. Manga MM, Fowotade A, Abdullahi YM, El-Nafaty AU, Adamu DB, Pindiga HU, Bakare RA, Osoba AO. Epidemiological patterns of cervical human papillomavirus infection among women presenting for cervical cancer screening in North-Eastern Nigeria. *Infectious Agents and cancer*. 2015 Dec;10(1):1-9.
28. Kairithia MF, Okello BN, Kamau WA. Socio-economic and demographic determinants of Human Papilloma Virus (HPV) vaccine awareness among urban women aged 18-45 years in Embakasi, Nairobi, Kenya. *East African Medical Journal*. 2016 May 31;93(4):145-50.